oru.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Topoisomerase IIα mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia
Department of Medicine, Örebro University Hospital, Örebro.
Clinical Research Centre, Örebro University Hospital, Örebro.
Department of Clinical Hematology, Karolinska University Hospital, Huddinge, Stockholm; Karolinska Institute, Stockholm.
Department of Clinical Hematology, Karolinska University Hospital, Huddinge, Stockholm; Karolinska Institute, Stockholm.
Vise andre og tillknytning
2007 (engelsk)Inngår i: International Journal of Oncology, ISSN 1019-6439, Vol. 31, nr 1, s. 153-160Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

The objective of this study was to correlate the expression of topoisomerase (topo) IIalpha to in vitro drug sensitivity and to the clinical outcome in patients with acute leukaemia. Leukaemic cells were isolated from bone marrow or blood from 94 patients. Topo IIalpha mRNA (n=58) and protein (n=60) expression was determined by real-time RT-PCR and flow cytometry, respectively. In both groups, chemosensitivity testing by a bioluminescence ATP assay was performed to a variable extent for both topo IIalpha poisons and non-topo IIalpha targeting drugs. Topo IIalpha mRNA expression varied with relative values ranging from 0.03 to 14.20 (median 1.10). The median value for topo IIalpha protein-positive cells was 23% (range 0-99%). Cell samples from patients with a high (>median value) percentage of topo IIalpha-positive cells were significantly more sensitive to the topo IIalpha active drugs etoposide and daunorubicin, and showed a borderline value for idarubicin (p=0.08), while there was no difference for non-topo IIalpha targeting drugs. However, we did not find any significant differences in mRNA expression or the percentage of topo IIalpha-positive cells in patients who achieved complete remission after at most two induction courses compared with those who did not, nor did we find any difference in survival when patients with high mRNA expression/percentage of topo IIalpha-positive cells were compared with patients with low values. We conclude that expression of topo IIalpha, determined as percentage of topo IIalpha-positive cells, in leukaemic cells correlates to chemosensitivity in vitro against topoisomerase poisons but that it does not predict clinical outcome in acute leukaemia.

sted, utgiver, år, opplag, sider
Athens: Editorial Academy of the International Journal of Oncology , 2007. Vol. 31, nr 1, s. 153-160
Emneord [en]
topoisomerase IIa, acute leukaemia, drug resistance, prognosis, reverse transcriptase-polymerase chain reaction, flow cytometry
HSV kategori
Forskningsprogram
Medicin; Biomedicin
Identifikatorer
URN: urn:nbn:se:oru:diva-10516PubMedID: 17549416Scopus ID: 2-s2.0-34548571944OAI: oai:DiVA.org:oru-10516DiVA, id: diva2:313642
Tilgjengelig fra: 2010-04-27 Laget: 2010-04-27 Sist oppdatert: 2017-12-12bibliografisk kontrollert
Inngår i avhandling
1. Biological markers in breast cancer and acute leukaemia with focus on drug resistance
Åpne denne publikasjonen i ny fane eller vindu >>Biological markers in breast cancer and acute leukaemia with focus on drug resistance
2010 (engelsk)Doktoravhandling, med artikler (Annet vitenskapelig)
sted, utgiver, år, opplag, sider
Örebro: Örebro universitet, 2010. s. 68
Serie
Örebro Studies in Medicine, ISSN 1652-4063 ; 43
Emneord
Breast cancer, acute leukaemia, drug resistance, toposiomerase IIa, BCRP, HER2, SLC25A43, flow cytometry, real time PCR, whole genome screening
HSV kategori
Forskningsprogram
Biomedicin
Identifikatorer
urn:nbn:se:oru:diva-10519 (URN)978-91-7668-724-6 (ISBN)
Disputas
2010-05-21, Bohmanssonsalen, Universitetssjukhuset, Örebro, 13:00 (svensk)
Opponent
Veileder
Tilgjengelig fra: 2010-04-27 Laget: 2010-04-27 Sist oppdatert: 2017-10-18bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

PubMedScopus

Personposter BETA

Uggla, BertilTina, ElisabetSirsjö, AllanTidefelt, Ulf

Søk i DiVA

Av forfatter/redaktør
Uggla, BertilTina, ElisabetSirsjö, AllanTidefelt, Ulf
Av organisasjonen
I samme tidsskrift
International Journal of Oncology

Søk utenfor DiVA

GoogleGoogle Scholar

pubmed
urn-nbn

Altmetric

pubmed
urn-nbn
Totalt: 495 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf